# OnCo record neo-811 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/neo-811/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "neo-811" ;
  schema:name "NEO-811"@en ;
  schema:alternateName "NEO811"@en ;
  schema:description "NEO-811 is an experimental molecular glue degrader from Neomorph, in phase 1 trials for clear cell renal cell carcinoma."@en ;
  schema:url <https://onco.cc/drugs/neo-811/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://neomorph.com/pipeline/>, <https://neomorph.com/press-release/neomorph-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-neo-811-for-the-treatment-of-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma/>, <https://neomorph.com/press-release/neomorph-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-neo-811-for-the-treatment-of-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma/>, <https://clinicaltrials.gov/search?intr=NEO-811> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Molecular glue degrader (cereblon-dependent)" ;
  onco:cancers <https://onco.cc/cancers/clear-cell-rcc/> ;
  onco:targets <https://onco.cc/targets/arnt/> ;
  onco:companies <https://onco.cc/companies/neomorph/> ;
  onco:trials <https://onco.cc/trials/nct07300241/> .